The purpose of this study is to evaluate the skin quality improvement and colonizationefficacy following the application of probiotic Micrococcus luteus Q24 (BLIS Q24) to theface from a serum format in healthy adults.
This is a randomized double-blind baseline controlled pilot study with no crossover for
the assessment of any changes to the microbial make-up of the skin (The local skin
microbiome), detection of colonization by the probiotic bacterium (BLIS Q24) on the skin
and to evaluate the changes in skin quality parameters following topical application of
probiotic in a serum format.
Other: Active Comparator: Study Group A: Blis Q24 Serum at higher dose
Active Comparator: Study Group A: Blis Q24 Serum at 1e7 cfu/ dose (Active)
Other: Active Comparator: Study Group B: Blis Q24 Serum at lower dose
Active Comparator: Study Group B: Blis Q24 Serum at 1e6 cfu/ dose (Active)
Inclusion criteria:
1. In general good health 18 - 80 years of age.
2. Practice good general body hygiene.
Exclusion criteria:
1. Have a history of autoimmune disease or are immunocompromised (have a weakened
immune system).
2. Are on concurrent antibiotic therapy or regular antibiotic use within the last 1
week.
3. People with allergies or sensitivity to dairy.
4. People with an open wound on the Blis Q24 application sites.
Blis Technologies Ltd
Dunedin, Otago, New Zealand
Not Provided